Background: An aging population, increased use of immunosuppressive therapy and an increase in patients with risk factors for tuberculosis have induced changes in the clinical features of pulmonary tuberculosis in Japan. Objective: To investigate transitional changes in the clinical features of recent patients with pulmonary tuberculosis. Methods: This study analyzed 820 patients with pulmonary tuberculosis who were culture positive for Mycobacterium tuberculosis in the Kawasaki Medical School Hospital and ten associated community hospitals between January 1986 and December 2005 (406 patients between January 1986 and December 1995 and 414 patients between January 1996 and December 2005). Results: The characteristic clinical features of the latter period were as follows: (1) an increase in the percentages of patients with both malignant diseases and collagen vascular diseases, (2) a decrease in the proportion of patients with obvious clinical symptoms, (3) an increase in the number of microbiologically smear-positive patients, (4) an increase in the percentages of patients with atypical radiological findings, (5) no change in the incidence of multidrug-resistant M. tuberculosis and (6) no change in the rate of the effect of treatment or prognosis. Conclusions: The findings of an increase in atypical features may be related to the increase in immunocompromised patients and should therefore be investigated further. Performance of acid-fast bacillus examination is extremely important because a good prognosis can be achieved if an accurate diagnosis is established as soon as possible and the resistance of M. tuberculosis to antituberculous drugs has not progressed.

Keywords:
Immunosuppressive patients, Pulmonary tuberculosis, Transitional change
1.
Ohmori M, Ishikawa N, Yoshiyama T, et al: Current epidemiological trend of tuberculosis in Japan. Int J Tuberc Lung Dis 2002;6:415–423.
2.
Guzman CP, Cruz AT, Velarde HV, et al: Progressive age-related changes in pulmonary tuberculosis images and the effect of diabetes. Am J Respir Crit Care Med 2000;162:1728–1740.
3.
Ikezoe J, Takeuchi N, Johkoh M, et al: CT appearance of pulmonary tuberculosis in diabetes and immunocompromised patients: comparison with patients who had no underlying disease.Am J Roentogenol 1992;159:1175–1179.
4.
Nemery B, Yew WW, Albent R, et al: Tuberculosis, nontuberculous lung infection, pleural disorders, pulmonary function, respiratory muscles, occupational lung disease, pulmonary infections, and social issues in AJRCCM in 2004. Am J Respir Crit Care Med2005;171:554–562.
5.
Segerra F, Sherman DS, Aguero J, et al: Lower lung field tuberculosis. Chest 1974;65:522–526.
6.
Toyota T: Studies on the changes in clinical features of tuberculosis (in Japanese, abstract in English). Kekkaku1990;65:619–631.
7.
Schitrit D, Vertenshtein T, Shitrit AB, et al: The role of routine culture for tuberculosis lung during bronchoscopy in a nonendemic area: analysis of 300 cases and review of the literature.Am J Infect Control 2005;33:602–605.
8.
Tueller C, Chhajed PN, Buitrago-Tellez C, et al: Value of smear and PCR in bronchoalveolar lavage fluid in culture positive pulmonary tuberculosis. Eur Respir J2005;20:767–772.
9.
Reisner D: Pulmonary tuberculosis of the lower lobe. Arch Intern Med 1935;56:258–280.
10.
Miyazaki N, Matsuzaki Y, Ninomiya K, et al: Lower lung field tuberculosis (in Japanese, abstract in English).Kekkaku 1993;68:589–596.
11.
Pratt-Johnson JH: Observations on lower lobe tuberculosis. Br J Dis Chest 1959;53:385–389.
12.
Palmer PES: Pulmonary tuberculosis – usual and unusual radiographic presentations. Semin Roentogenol 1979;14:204–243.
13.
Keane J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–1104.
14.
Mutlu GM, Mutlu EA, Mellmeyer A, et al: Pulmonary adverse events of anti-tumor necrosis factor-α antibody therapy. Am J Med 2006;119:639–646.
15.
Hirano K, Kazumi Y, Abe C, et al: Resistance to antituberculous drugs in Japan. Tuber Lung Dis 1996;77:130–135.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.